Abstracts tagged "angiopoietin"

Abstract Number: 1764 • 2018 ACR/ARHP Annual Meeting
The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Yoko Wada¹, Takeshi Kuroda², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Health Administration Center, Niigata University, Niigata, Japan, ³Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) are antagonistic ligands which bind with similar affinity to the extracellular domain of the tyrosine kinase with Ig-like and…
Abstract Number: 2691 • 2018 ACR/ARHP Annual Meeting
Increased Plasma Angiopoietin-2 in Systemic Sclerosis: Potential for Use As a Biomarker of Vasculopathy and Fibrosis
Victoria Flower^1,2, Shaney Barratt^3,4, Darren Hart⁵, Amanda MacKenzie², Jacqueline Shipley⁵, Stephen Ward² and John Pauling^1,2, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom, ²Centre for Therapeutic Innovations & Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴North Bristol NHS Trust, Bristol, United Kingdom, ⁵Clinical Measurement Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom
Background/Purpose: Angiogenic pathways are likely to contribute to pathogenesis of both vasculopathy and fibrosis in Systemic sclerosis (SSc). The angiogenic actions of Angiopoietins (pro-angiogenic Ang1…
Abstract Number: 2232 • 2013 ACR/ARHP Annual Meeting
Neutralization of Angiopoietin-2 Enhances the Efficacy of Anti-Tumor Necrosis Factor-Alpha Treatment in a Mouse Model of Rheumatoid Arthritis by Decreasing Cellular Infiltration into the Joint and Protecting Bone
Brian Naiman, Sean Turman, William Iverson, Ronald Herbst, Tomas Mustelin and Jane Connor, Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: It has recently been established that >75% of patients on methotrexate and a biologic do not achieve complete remission based on the new definition…
Abstract Number: 1602 • 2012 ACR/ARHP Annual Meeting
Tie2 Signalling Induces a Pro-Inflammatory and Pro-Angiogenic Phenotype in Differentiated Macrophages, Independently of Macrophage Polarization Conditions, and Contributes to Production of Cytokines Elevated in Early Rheumatoid Arthritis
Samuel Garcia¹, Sarah Krausz², Carmen A. Ambarus³, Bea Malvar Fernandez², Dominique L. Baeten⁴, Paul P. Tak⁵ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Department Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Angiopoietin (Ang) -1 and -2 signalling to the Tie2 tyrosine kinase receptor has an essential role in blood vessel remodeling and angiogenesis. Ang-1, Ang-2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].